Hikma Pharmaceuticals (H5P) Stock Forecast & Price Target

Compare

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

H5P Analyst Ratings

Moderate Buy

2 Buy

0 Hold

1 Sell

Based on 3 analysts giving stock ratings to

Hikma

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

H5P Stock 12 Month Forecast

Average Price Target

€26.97

▲(50.64% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is €26.97 with a high forecast of €27.54 and a low forecast of €26.39. The average price target represents a 50.64% change from the last price of €17.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"€16","19":"€19","22":"€22","25":"€25","28":"€28"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":27.538776000000002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€27.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.9650515,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€26.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.391327,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€26.39</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,19,22,25,28],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.1,18.826059692307695,19.552119384615388,20.278179076923077,21.00423876923077,21.730298461538464,22.456358153846157,23.182417846153847,23.90847753846154,24.634537230769233,25.360596923076926,26.08665661538462,26.812716307692313,{"y":27.538776000000002,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.1,18.78192703846154,19.463854076923077,20.145781115384615,20.827708153846157,21.509635192307694,22.191562230769232,22.87348926923077,23.555416307692308,24.23734334615385,24.919270384615388,25.601197423076925,26.283124461538463,{"y":26.9650515,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.1,18.737794384615388,19.37558876923077,20.013383153846156,20.65117753846154,21.288971923076925,21.926766307692308,22.564560692307694,23.202355076923077,23.840149461538463,24.477943846153845,25.11573823076923,25.753532615384614,{"y":26.391327,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.329,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.361,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.062,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.062,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.427,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.062,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.273,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€27.54

Average Price Target€26.97

Lowest Price Target€26.39

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Beatrice Fairbairn

Berenberg Bank

€26.39

Buy

47.44%

Upside

Reiterated

01/22/26

Berenberg Bank Sticks to Their Buy Rating for Hikma Pharmaceuticals (HIK)

Kane Slutzkin

Deutsche Bank

€28.69→€27.54

Buy

53.85%

Upside

Reiterated

01/09/26

Deutsche Bank Remains a Buy on Hikma Pharmaceuticals (HIK)

James Gordon CFA

Barclays

―

Sell

―

Downgraded

01/06/26

Hikma Pharmaceuticals downgraded to Underweight from Equal Weight at BarclaysHikma Pharmaceuticals downgraded to Underweight from Equal Weight at Barclays

Unknown Analyst

Peel Hunt

Not Ranked

Peel Hunt

€24.9

Buy

39.10%

Upside

Reiterated

11/07/25

Peel Hunt Keeps Their Buy Rating on Hikma Pharmaceuticals (HIK)

James Vane

Jefferies

€27.08

Buy

51.28%

Upside

Reiterated

11/07/25

Hikma Pharmaceuticals (HIK) Receives a Buy from Jefferies

Zain Ebrahim

J.P. Morgan

€27.54

Buy

53.85%

Upside

Reiterated

11/06/25

Hikma Pharmaceuticals (HIK) Gets a Buy from J.P. Morgan

Alistair Campbell

RBC Capital

€30.12

Buy

68.27%

Upside

Reiterated

08/11/25

Hikma Pharmaceuticals (HIK) Gets a Buy from RBC Capital

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

€27.31

Hold

52.57%

Upside

Initiated

06/09/25

Hikma Pharmaceuticals (HIK) Initiated with a Hold at Bank of America Securities

Victor Floc'h

Exane BNP Paribas

€30.41

Buy

69.87%

Upside

Initiated

05/14/25

BNP Paribas Exane Starts Hikma Pharmaceuticals Plc (HIK:LN) (HKMPF) at OutperformBNP Paribas Exane analyst Victor Floch initiates coverage on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) with a Outperform rating and a price target of GBP26.50.

Christian Glennie

Stifel Nicolaus

€30.41

Buy

69.87%

Upside

Reiterated

04/24/25

Promising Financial Outlook and Strategic Positioning of Hikma Pharmaceuticals: A Buy Recommendation by Christian Glennie

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Beatrice Fairbairn

Berenberg Bank

€26.39

Buy

47.44%

Upside

Reiterated

01/22/26

Berenberg Bank Sticks to Their Buy Rating for Hikma Pharmaceuticals (HIK)

Kane Slutzkin

Deutsche Bank

€28.69→€27.54

Buy

53.85%

Upside

Reiterated

01/09/26

Deutsche Bank Remains a Buy on Hikma Pharmaceuticals (HIK)

James Gordon CFA

Barclays

―

Sell

―

Downgraded

01/06/26

Hikma Pharmaceuticals downgraded to Underweight from Equal Weight at BarclaysHikma Pharmaceuticals downgraded to Underweight from Equal Weight at Barclays

Unknown Analyst

Peel Hunt

Not Ranked

Peel Hunt

€24.9

Buy

39.10%

Upside

Reiterated

11/07/25

Peel Hunt Keeps Their Buy Rating on Hikma Pharmaceuticals (HIK)

James Vane

Jefferies

€27.08

Buy

51.28%

Upside

Reiterated

11/07/25

Hikma Pharmaceuticals (HIK) Receives a Buy from Jefferies

Zain Ebrahim

J.P. Morgan

€27.54

Buy

53.85%

Upside

Reiterated

11/06/25

Hikma Pharmaceuticals (HIK) Gets a Buy from J.P. Morgan

Alistair Campbell

RBC Capital

€30.12

Buy

68.27%

Upside

Reiterated

08/11/25

Hikma Pharmaceuticals (HIK) Gets a Buy from RBC Capital

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

€27.31

Hold

52.57%

Upside

Initiated

06/09/25

Hikma Pharmaceuticals (HIK) Initiated with a Hold at Bank of America Securities

Victor Floc'h

Exane BNP Paribas

€30.41

Buy

69.87%

Upside

Initiated

05/14/25

Christian Glennie

Stifel Nicolaus

€30.41

Buy

69.87%

Upside

Reiterated

04/24/25

Promising Financial Outlook and Strategic Positioning of Hikma Pharmaceuticals: A Buy Recommendation by Christian Glennie

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hikma Pharmaceuticals

3 Months

xxx

Success Rate

3/7 ratings generated profit

Average Return

+2.77%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of +2.77% per trade.

1 Year

James VaneJefferies

Success Rate

5/14 ratings generated profit

Average Return

-6.61%

a rating ―

Copying James Vane's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -6.61% per trade.

2 Years

xxx

Success Rate

5/14 ratings generated profit

Average Return

-3.49%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 35.71% of your transactions generating a profit, with an average return of -3.49% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

H5P Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, H5P has received 2 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. H5P average Analyst price target in the past 3 months is 26.97.

Each month's total comprises the sum of three months' worth of ratings.

H5P Financial Forecast

H5P Earnings Forecast

The previous quarter’s earnings for H5P were €0.91.

H5P Sales Forecast

The previous quarter’s earnings for H5P were €1.44B.

H5P Stock Forecast FAQ

What is DE:H5P’s average 12-month price target, according to analysts?

Based on analyst ratings, Hikma Pharmaceuticals PLC’s 12-month average price target is 26.97.

What is DE:H5P’s upside potential, based on the analysts’ average price target?

Hikma Pharmaceuticals PLC has 50.64% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Hikma Pharmaceuticals PLC a Buy, Sell or Hold?

Hikma Pharmaceuticals PLC has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 1 sell ratings.

What is Hikma Pharmaceuticals PLC’s share price target?

The average share price target for Hikma Pharmaceuticals PLC is 26.97. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €27.54 ,and the lowest forecast is €26.39. The average share price target represents 50.64% Increase from the current price of €17.9.

What do analysts say about Hikma Pharmaceuticals PLC?

Hikma Pharmaceuticals PLC’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of Hikma Pharmaceuticals PLC?

To buy shares of DE:H5P, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Hikma Pharmaceuticals (H5P) Stock Forecast & Price Target

H5P Analyst Ratings

H5P Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Hikma Pharmaceuticals

H5P Analyst Recommendation Trends

H5P Financial Forecast

H5P Earnings Forecast

H5P Sales Forecast

H5P Stock Forecast FAQ

Detailed List of Analyst Forecasts